Related Experiment Video
Updated: Jan 12, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Cost-Effectiveness of Once-Weekly Insulin Icodec versus Daily Basal Insulins in Chinese Adults with T2DM: A
Zeyu Xie1, Weishang Deng2, Zhuoru Liang1
1Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, Guangdong Province, People's Republic of China.
Objective:
This study evaluated the long-term cost-effectiveness of once-weekly insulin icodec versus daily basal insulins in Chinese adults with type 2 diabetes mellitus (T2DM) across treatment backgrounds (insulin-naïve to basal-bolus users).
Methods:
Using the UKPDS-OM2.1 model calibrated to ONWARDS trial data (1-5), we simulated lifetime outcomes over a 40-year horizon. Cost-utility analyses incorporated direct healthcare costs, complication utilities. Uncertainties were addressed using one-way and probabilistic sensitivity analyses. Scenario analyses explored pricing thresholds and adherence assumptions.
Results:
Insulin icodec demonstrated cost-effectiveness versus degludec in insulin-naïve populations (ICER=$24974.29, below China's 3 times WTP threshold) but not versus glargine U100 (ICER=$45544.68) and once-daily basal insulin (ICER=$76877.59). For basal and basal-bolus insulin treated patients, insulin icodec does not offer long-term cost-effectiveness advantages over either insulin degludec and insulin glargine U100. One-way sensitivity analyses identified the simulation time horizon and discount rate as the most influential parameters, with probabilistic sensitivity analyses confirming the robustness of these findings. Scenario analyses demonstrated that insulin icodec's would become cost-effective compared to basal insulins when patients were willing to pay an additional $150 annually.
Conclusion:
Insulin icodec offers cost-saving potential versus degludec in insulin-naïve T2DM patients. For basal and basal-bolus-treated patients, the clinical use of icodec needs to be critically evaluated for cost burden, and it is recommended that it be used preferentially in patients who are sensitive to the frequency of injections.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Drug Dosing: Obese Patients
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

